Amitkumar J. Vyas, Jayshree P. Godhaniya, Ajay I. Patel, Ashok B. Patel, Nilesh K. Patel, Alpesh Chudasama, Sunny R. Shah
Amitkumar J. Vyas1, Jayshree P. Godhaniya1*, Ajay I. Patel1, Ashok B. Patel1, Nilesh K. Patel1, Alpesh Chudasama2, Sunny R. Shah1
1Pharmaceutical Quality Assurance Department, B.K. Mody Government Pharmacy College, Rajkot, Gujarat, India.
2Amneal Pharmaceutical Pvt. Ltd., 1 New England Avenue, Piscataway, NJ 07936, USA.
Volume - 11,
Issue - 2,
Year - 2021
The control of potentially mutagenic and carcinogenic impurities in pharmaceutical products is key importance in evaluating carcinogenic risk to humans. The recent discovery of nitrosamine impurities in some marketed pharmaceuticals has increased the risk of their mutagenic and carcinogenic potential. According to the International Agency for Research on Cancer (IARC), nitrosamine is the chemical classified as a probable human carcinogen. Nitrosamine impurities are known to be mutagenic and carcinogenic, very small exposure of these impurities can lead to cancer. These impurities may be produced and get incorporated into drug substances or drug products by a reagent, catalyst, solvent, or raw materials used in the process of manufacturing. The presence of nitrosamine impurities in angiotensin II receptor blocker (ARB) drugs containing tetrazole ring has caused worldwide product recalls. The various regulatory authorities have published the press release or notice regarding the control of these impurities with the interim limit. In 2007, the European medicines agency (EMA) suspended the marketing authorization of Viracept, because of the presence of elevated levels of ethyl methane sulfonate, in the drug product. Validated analytical methods are used to identify and quantify these impurities to the trace level at a given interim limit.
Cite this article:
Amitkumar J. Vyas, Jayshree P. Godhaniya, Ajay I. Patel, Ashok B. Patel, Nilesh K. Patel, Alpesh Chudasama, Sunny R. Shah. A Review on Carcinogenic Impurities Found in Marketed Drugs and Strategies for its Determination by Analytical Methods. Asian Journal of Pharmaceutical Analysis. 2021; 11(2):159-9. doi: 10.52711/2231-5675.2021.00028
Amitkumar J. Vyas, Jayshree P. Godhaniya, Ajay I. Patel, Ashok B. Patel, Nilesh K. Patel, Alpesh Chudasama, Sunny R. Shah. A Review on Carcinogenic Impurities Found in Marketed Drugs and Strategies for its Determination by Analytical Methods. Asian Journal of Pharmaceutical Analysis. 2021; 11(2):159-9. doi: 10.52711/2231-5675.2021.00028 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2021-11-2-18
1. Landge AK, Deshmukh VK and Chaudhar SR. Impurities in Pharmaceuticals- A Review. Journal of Current Pharma Research. 2013; 4(1): 1105-1116.
2. ICH – Harmonized Tripartite Guideline, “Impurity in new drug substance Q3(A)”, International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2006.
3. Poonam R. Songire, Smita Aher, Prof. Dipti Phadtare, Saudagar R. B. Review on Guideline on Elemental Impurities. Asian J. Research Chem. 2016; 9(5): 226-232. doi: 10.5958/0974- 4150.2016.00039.0
4. Shefali Patel, Madhavi Apte. A Review on Signicances of Impurity Proling a Review on Signicances of Impurity Proling. Res. J. Pharm. Dosage Form. and Tech. Jan.-Mar. 2016; 8(1): 31-36. doi: 10.5958/0975-4377.2016.00005.7
5. ICH – Harmonized Tripartite Guideline, “Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7”, International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2006.
6. International Agency for Research on Cancer, November 2020: https://wiki.cancer.org.au/policy/IARC_classifications
7. Thresher A. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Regulatory Toxicology and Pharmacology. 2020; DOI: https://doi.org/10.1016/ j.yrtph.2020.104749.
8. IARC classification, November 2020: http://monographs.iarc.fr/ ENG/Classification/index.php
9. Andrea V. Eads. Pharmacists are key in interpreting clinical implications of N-nitrosodimethylamine contamination in medications. Journal of the American Pharmacists Association. 2020; 1-5.
10. Georgi T, Ivanka T. Drug-Induced Melanoma: Irbesartan Induced Cutaneous Melanoma! First Description in the World Literature! Open Access Maced J Med Sc. 2019; 7(1): 114-116.
11. NDMA, a contaminant found in multiple drugs, has industry seeking sources and solutions, November 2020: https://cen.acs.org/ pharmaceuticals/pharmaceutical-chemicals/NDMA-contaminant-found-multiple-drugs/98/i15
12. FDA Requests Removal of All Ranitidine Products (Zantac) from the Market November 2020: https://www.fda.gov/news-events/ press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market.
13. Jennifer A, Wagner and Jennifer M. Commentary medicine and Media: The Ranitidine Debate. Clinical and Translational Science. 2020; doi:10.1111/cts.12753
14. Teng Z, William A. Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine. Carcinogenesis. 2016; 37: 625-634. doi:10.1093/carcin/bgw034
15. NDMA in drugs, Ranitidine, November 2020: https://cen.acs.org/ pharmaceuticals/Reactions/98/i21
16. Dr. Shaikh T, Dr. Gosar A and Dr. Sayyed H. Nitrosamine Impurities in Drug Substances and Drug Products. Journal of Advances in Pharmacy Practices. 2020; 2: 48-57.
17. EMA overview: Lessons learnt from presence of N-nitrosamine impurities in sartan medicines.
18. EMA Assessment report: angiotensin-II-receptor antagonists (sartans) containing a tetrazole group, Referral under Article 31 of Directive 2001/83/EC.
19. Charoo NA et al. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities. American Association of Pharmaceutical Scientists. 2019; 20: 166. DOI: 10.1208/s12249-019-1376-1
20. Parr MK, Joseph JF. NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines. Journal of Pharmaceutical and Biomedical Analysis.2019; 164: 536-549. DOI: https://doi.org/10.1016/ j.jpba.2018.11.010
21. What would cause NDMA contamination in valsartan? November 2020: https://www.quora.com/What-would-cause-NDMA-contamination-in-valsartan
22. NDMA, November 2020: https://pubchem.ncbi.nlm.nih.gov/ compound/n-nitrosodimethylamine
23. Sulc M, Hodek P, Stiborová F. The binding affinity of carcinogenic N-nitrosodimethylamine and N-nitrosomethylaniline to cytochromes P450 2B4, 2E1 and 3A6 does not dictate the rate of their enzymatic N-demethylation. Gen. Physiol. Biophys. 2010; 29: 175-85.
24. N-Nitrosodimethylamine in Drinking-water Background document for development of WHO Guidelines for Drinking-water Quality
25. Bartsch H, Neill TKO and Schulte-Hermann R. Relevance of n-nitroso compounds to human cancer: exposures and mechanisms. IARC, 1986.
26. NMBA November 2020: https://www.caymanchem.com/product/ 30911/n-nitroso-n-methyl-4-aminobutyric-acid
27. Darker side of technology- A game changer. IDMA, 2019.
28. European Medicines Agency. Temporary interim limits for NMBA, DIPNA and EIPNA impurities in sartan blood pressure medicines. November 2020.
29. U.S. Food and Drug Administration. Updates and press announcements on angiotensin II receptor blocker (ARB) recalls (Valsartan, Losartan, and Irbesartan), November 2020. https:// www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcementsangiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan
30. Taniguchi J et al. Nitrosamines in Pharmaceuticals: Toxicity, Risk Analysis, Chemistry, and Test Methods.American pharmaceuticals review. 2020. Avalible from URL: https:// www.americanpharmaceuticalreview.com/Featured-Articles/ 561484-Nitrosamines-in-Pharmaceuticals-Toxicity-Risk-Analysis-Chemistry-and-Test-Methods/
31. FDA works to mitigate shortages of rifampin and rifapentine after manufacturers find nitrosamine impurities, November 2020: https://www.fda.gov/drugs/drug-safety-and-availability/fda-works-mitigate-shortages-rifampin-and-rifapentine-after-manufacturers-find-nitrosamine
32. FDA addresses nitrosamines in TB drugs, November 2020: https:// www.raps.org/news-and-articles/news-articles/2020/8/fda-addresses-nitrosamines-in-tb-drugs
33. US FDA allows supply of 2 tuberculosis drugs with impurities to avoid shortages, November 2020: https://www.spglobal.com/ marketintelligence/en/news-insights/latest-news-headlines/us-fda-allows-supply-of-2-tuberculosis-drugs-with-impurities-to-avoid-shortages-60114091
34. N,N-Dimethylformamide, November 2020: https:// pubchem.ncbi.nlm.nih.gov/compound/N_N-Dimethylformamide
35. Valisure Detects High Levels of DMF in Valsartan, November 2020: https://www.valisure.com/blog/valisure-news/valisure-detects-high-levels-of-dmf-in-valsartan/
36. More trouble for valsartan with discovery of Fourth carcinogen, November 2020: https://www.pharmacist.com/article/more-trouble -valsartan-discovery-fourth-carcinogen#:~:text=FDA%20has%20 been%20informed%20that,Organization%20as%20a%20probable%20carcinogen
37. N,N-DIMETHYLFORMAMIDE, Concise International Chemical Assessment Document 31,WHO.
38. N,N- Dimethylformamide IARC monograph.1989,1999.
39. Ethyl methanesulfonate, November 2020: https:// pubchem.ncbi.nlm.nih.gov/compound/Ethyl-methanesulfonate
40. David PE, David JS. Drug substances presented as sulfonic acid salts: overview of utility, safety and regulation. Journal of Pharmacy and Pharmacology. 2009; 61: 269–278.
41. Muller L et al. Ethyl methanesulfonate toxicity in Viracept-A comprehensive human risk assessment based on threshold data for genotoxicity. Toxicology Letters, 2009: 317–329. Doi:10.1016/ j.toxlet.2009.04.003.
42. Shaik KM et al. Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques Critical Reviews in Analytical Chemistry, 2020.
43. Sahoo CK et al. Validation of Analytical Procedures- A Review. Asian J. Pharm. Ana. 2018; 8(2): 109-116. doi: 10.5958/2231-5675.2018.00021.2
44. Lima H, Yun-Suk Ohb and Shin H. Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2020.
45. Khan H and Ali J. Identication of Impurities and Degradation Productsin Pharmaceutical Products- Role of Hyphenated Techniques. Asian J. Pharm. Ana. 2017; 7(1): 31-35. doi: 10.5958/ 2231-5675.2017.00006.0
46. Dubey RD. Mass Spectroscopy: A Versatile Analytical Technique. Research J. Science and Tech. 2011; 3(2): 55-64.
47. Dwivedi A et al. Impurity Proling With Use of Hyphenated Techniques. Asian J. Research Chem. 2012; 5(7): 875-881.
48. Pramod K et al. An Overview: LC-MS as Tool of sample Extraction and Quantication in Bioanalytical Laboratories. Asian J. Pharm. Ana. 2020; 10(3): 165-172. doi: 10.5958/2231-5675.2020.00030.7
49. Naseeh PK and Ranjan A. A review article on prevalence of colorectal cancer with ranitidine. International Journal of Modern Pharmaceutical Research. 2020; 7-13.
50. USFDA: Liquid Chromatography-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of MNP in Rifampin and CPNP in Rifapentine Drug Substance and Drug Product, 2019.
51. Khan H, Javed A. UHPLC: Applicationsin Pharmaceutical Analysis. Asian J. Pharm. Ana. 2017; 7(2): 124-131. doi: 10.5958/ 2231-5675.2017.00020.5
52. Ramraje GR. A Brief Review on: Separation Techniques Chromatography. Asian J. Pharm. Ana. 2020; 10(4): 231-238. doi: 10.5958/2231-5675.2020.00041.1
53. Khan H. Analytical Method Development in Pharmaceutical Research: Stepsinvolved in HPLC Method Development. Asian J. Pharm. Res. 2017; 7(3): 203-207. doi: 10.5958/2231-5691.2017.00031.4
54. USFDA: Development and validation of a RapidFire-MS/MS method for screening of nitrosamine carcinogen impurities N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), N-Nitrosodiisopropylamine (NDIPA), NNitrosodibutylamine (NDBA) and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) in API.